The Therapeutic Vaccine Potential of MIS416 Adjuvant - Linking innate and adaptive immunity through the activation of multiple innate host defenses. - BioPharm International

ADVERTISEMENT

The Therapeutic Vaccine Potential of MIS416 Adjuvant
Linking innate and adaptive immunity through the activation of multiple innate host defenses.


BioPharm International Supplements


Activating Broad-Spectrum, Tumor-Killing Mechanisms


Figure 5. MIS416 therapy suppresses weight loss and mortality after infection with type A influenza. (A) C57BL/6 mice (n = 10 per group) were infected with 0.3 LD-50 influenza A strain A/PR/8/34 (H1N1). The following day, animals received vehicle control (saline), 50 g MIS416, or 250 g of MIS416 intravenously. Weights were monitored daily. Where indicated (*), MIS416 therapy significantly reduced weight loss. (B) Mice were infected as described above. Animals that lost more than 30% of their initial weight were considered moribund and euthanized. Data are pooled from two independent experiments (n = 15 total mice per group). The reduced morbidity of animals treated with MIS416 was statistically significant (p = 0.035 by Log rank test).

Figure 6. Enhancement of purified human NK spontaneous killing activity following stimulation with MIS416. Human CD56+ cells were purified from whole blood to 99% and cultured for 40 hours with no stimulus, known NK activating agents IL-2 (500 U/mL) and IL-12 (50 ng/mL) or with MIS416 (40, 20, 10, and 5 g/mL). Stimulated NK cells were subsequently tested for cytotoxicity against fluorescently labelled NK sensitive K562 tumor targets at effector:target ratios of 5:1, 2:1, and 1:1. Tumor cell killing was determined after four hours by flow cytometric analysis of viability dye uptake (propidium iodide) of gated, fluorescent K562 targets.
Therapeutic vaccines administered to cancer patients are designed to treat cancer by stimulating the immune system to recognize and attack human cancer cells without harming normal cells, and to overcome the immune system's tolerance to cancer antigens.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here